Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.
Br J Dermatol
; 190(4): 559-564, 2024 Mar 15.
Article
in En
| MEDLINE
| ID: mdl-37931161
Full text:
1
Database:
MEDLINE
Main subject:
Tumor Necrosis Factor-alpha
/
Hematologic Tests
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Year:
2024
Type:
Article